<DOC>
	<DOCNO>NCT02791373</DOCNO>
	<brief_summary>The purpose study determine whether efficacy gemcitabine comparable efficacy standard chemotherapy vinorelbine mobilization autologous stem cell myeloma patient</brief_summary>
	<brief_title>Vinorelbine Gemcitabine Myeloma</brief_title>
	<detailed_description>Mobilization engraftment autologous peripheral blood progenitor cell ( PBPC ) newly diagnose multiple myeloma ( MM ) amyloidosis patient follow high dose chemotherapy PBPC support . Eligible symptomatic myeloma amyloidosis patient standard first-line induction treatment . Patients must fit subsequent consolidation high-dose chemotherapy melphalan autologous stem cell support . Chemotherapy vinorelbine give standard dose 35mg/m2 i.v . day 1 infusion 10 minute , ambulatory basis . Gemcitabine give standard dose 1250 mg/m2 i.v . 500ml NaCl 0.9 % ( sodium chlorid ) infusion 30 minute , ambulatory basis . G-CSF ( granulocyte-colony stimulating factor ) give 60 Mio s.c./d patient ≤ 69kg two daily dos 30 Mio 12 hour apart , 78 Mio s.c./d patient 70kg 89kg 48 Mio give morning 30 Mio give evening , 96 Mio s.c./d patient ≥ 90kg two daily dos 48 Mio . Patients randomize 1:1 ratio vinorelbine gemcitabine mobilization . Patients stratify accord ( A ) response induction treatment ( refractory/stable disease/partial response versus good partial response/complete response ) ( B ) peripheral neuropathy present versus absent mobilization . The high dose chemotherapy support autologous stem cell transplantation part study treatment . Standard high dose melphalan ( 200 mg/m2 ) use condition regimen . After transplantation , G-CSF give subject start day +6 day +11 PBPC re-infusion , dose 30 Mio per day patient ≤ 75kg , 48 Mio patient &gt; 75kg . Planned accrual chemotherapy vinorelbine give standard dose 35mg/m2 i.v . day 1 infusion 10 minute , ambulatory basis . Gemcitabine give standard dose 1250 mg/m2 i.v . 500ml NaCl 0.9 % infusion 30 minute , ambulatory basis . G-CSF give 60 Mio s.c./d patient ≤ 69kg two daily dos 30 Mio 12 hour apart , 78 Mio s.c./d patient 70kg 89kg 48 Mio give morning 30 Mio give evening , 96 Mio s.c./d patient ≥ 90kg two daily dos 48 Mio . Patients randomize 1:1 ratio vinorelbine gemcitabine mobilization . Patients stratify accord ( A ) response induction treatment ( refractory/stable disease/partial response versus good partial response/complete response ) ( B ) peripheral neuropathy present versus absent mobilization . The high dose chemotherapy support autologous stem cell transplantation part study treatment . Standard high dose melphalan ( 200 mg/m2 ) use condition regimen . After transplantation , G-CSF give subject start day +6 day +11 PBPC re-infusion , dose 30 Mio per day patient ≤ 75kg , 48 Mio patient &gt; 75kg . Planed accrual 136 patient 42 month .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Symptomatic myeloma amyloidosis patient standard firstline induction treatment . Patients must fit subsequent consolidation highdose chemotherapy melphalan autologous stem cell support . Standard induction chemotherapy comprise regimens include thalidomide , bortezomib , lenalidomide ( le 5 cycle ) , alone combination dexamethasone . Combinations novel agent allow well induction VAD ( vincristine , adriamycin dexamethasone ) regimen . Patient must age 1875 year , ECOG ( Eastern Cooperative Oncology Group ) &lt; 3 , give voluntary write informed consent . Patient follow laboratory value baseline : Platelets count &gt; 50 x 109/l without transfusion support within 7 day laboratory test . Absolute neutrophil count ( ANC ) &gt; 1.0 x 109/l without use colony stimulate factor . Creatinineclearance &gt; 40 ml/min Negative pregnancy test ( urine serum ) within 14 day prior registration woman childbearing potential . Patients childbearing potential must implement adequate measure ( hormonal treatment p.o . i.m. , intra uterine surgical device , latex condom ) avoid pregnancy study treatment additional 12 month . No pregnant lactating patient allow . Patients 4 cycle chemotherapy lenalidomide . Patients fit autologous stem cell transplantation Patients serious medical condition could potentially interfere completion treatment accord protocol would impair tolerance therapy prolong hematological recovery . Subject currently enrol another investigational trial receive investigational agent ( ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>